Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 3/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.39 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14881516 | 0.97 | LMNA (0.43) | LMNAHSD17B10NAMPTNTRK1IRAK4 | |
| SCHEMBL14897003 | 0.97 | LMNA (0.43) | LMNAHSD17B10NAMPTNTRK1IRAK4 | |
| SCHEMBL14897267 | 0.84 | NTRK1 (0.46) | NTRK1 | |
| SCHEMBL14897331 | 0.84 | NAMPT (0.43) | LMNAHSD17B10NAMPTNTRK1IRAK4 | |
| SCHEMBL14896812 | 0.82 | NTRK1 (0.41) | NTRK1IRAK4 | |
| SCHEMBL14897739 | 0.82 | NTRK1 (0.46) | NTRK1IRAK4 | |
| SCHEMBL14897368 | 0.82 | IRAK4 (0.46) | LMNANAMPTIRAK4POLBALDH1A1 | |
| SCHEMBL14896942 | 0.82 | IRAK4 (0.49) | LMNAHSD17B10NAMPTNTRK1IRAK4 | |
| SCHEMBL14897480 | 0.81 | IRAK4 (0.45) | LMNAHSD17B10NAMPTNTRK1IRAK4 | |
| SCHEMBL14881970 | 0.81 | NTRK1 (0.43) | NTRK1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2018-07-05 | — | — | US | disclosed |
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | LMNA 3264/4885HSD17B10 1258/4885NAMPT 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.